Work

Expanded RAS: Refining the Patient Population

Year: 2015

Type: editorial

Abstract: The era of precision medicine has changed the treatment paradigm for some cancers, but for others, the term precision is a stretch. New targets and therapies have broadened choices for patients with lung cancer or melanoma; however, in colorectal cancer (CRC), for example, the evolution of biomarkers has been primarily to inform whom not to treat rather than to identify the patients who will benefit from treatment. The refinements in CRC have been limiting rather than expansive; by broadening the definition of RAS mutations, fewer patients have multiple targeted options.

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.58.9325

Authors: Chloe E. Atreya, Ryan B. Corcoran, Scott Kopetz

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Harvard University, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute